It’s one of those things that feels obvious when you’re the one living it. Manage a chronic disease well, and you need less emergency care down the road.
Obesity is a chronic, metabolic disease. GLP-1s are remarkably effective at treating it, and they’re already linked to lower rates of diabetes, reduced cardiovascular events, and now, as I wrote about earlier, mounting evidence of reduced inflammation throughout the body.
Connect those dots and lower long-term healthcare costs should follow.
But “should follow” and “proven” are different things, and insurers have leaned hard on that gap for years. A new real-world study just gave them much less room to stand on.
15,843 Patients, One Real-World Test
The study looked at 15,843 adults over age 55, with an average age of 64.5, who were obese or overweight and had at least one weight-related complication. All subjects had started on Zepbound between November 2023 and September 2025.
Researchers pulled the data from Komodo’s Healthcare Map, a claims database covering more than 330 million people across U.S. health plans. They matched each Zepbound patient one-to-one with a similar person who didn’t start any GLP-1 medication. And they accounted for baseline health status, complications, and prior healthcare use.
This is the first study of its kind specifically in this age group, and it was published in the peer-reviewed journal Diabetes, Obesity and Metabolism.
The Savings Show Up Fast
Cost differences showed up fast and grew from there. At six months, patients on Zepbound had healthcare costs (not counting the medication itself) running up to 15% lower than the matched control group, a difference of up to $181 per person, per month.
By twelve months, that gap widened to as much as 38% lower, or up to $607 per person, per month.
The savings weren’t evenly spread across every kind of care either. This is exactly what you’d hope to see if this is a real effect and not statistical noise.
Patients on Zepbound had consistently lower rates of hospital admissions and emergency department visits, , mostly shows up a year or more down the road. That means it’s quite possibly on a different insurer’s books, for a patient who’s already moved on to a new job and/or a new plan.
while their routine outpatient and office visits went up.
That’s great news because it suggests people are proactively managing their health instead of waiting for a crisis.
A Detail That Speaks to the Coverage Fight
One detail in this new data speaks directly to the coverage fight happening right now. For adults enrolled in Medicare’s GLP-1 Bridge program, the estimated cost savings nearly covered the program’s monthly treatment cost by six months in, and fully exceeded it by twelve months.
In plain language, that means that within a year, the money saved on hospital visits and emergency care was outpacing what Medicare was spending to keep these patients on the medication in the first place.
In other words, it looks a lot like proof of success.
Looking At Study Limitations
As always, we should take a clear-eyed view of the study’s limitations.
First, this study was not a randomized trial. It used retrospective, observational data, so it shows a strong association rather than airtight proof of cause and effect.
In addition, Eli Lilly, the maker of Zepbound, funded and published it. This doesn’t make the findings invalid, of course. The paper underwent peer review at a well-respected journal. However, it’s always important to know who is funding a study and who stands to benefit from it.
Finally, the data didn’t include the drug’s actual net price, so researchers excluded Zepbound’s cost from the comparison entirely. That means this study shows the savings that could help offset the medication’s price, not a full accounting of whether the total cost of treatment nets out cheaper overall.
My Take On Who’s Really Holding the Bag
Here’s where I’ll step out of the research and into opinion, because I think there’s a perspective worth considering here.
I don’t believe “we don’t have the data yet” was ever really the whole story behind insurers dragging their feet on GLP-1 coverage.
People switch jobs, and therefore health plans, more often than they used to. Plus, employers shop around for new plans more frequently. An insurer paying for a GLP-1 today is fronting a real, immediate cost for a payoff that, if this study holds up
That’s not a science-based reason. It’s a reason grounded in who’s holding the bag when the savings finally arrive. And the patient’s health? That’s not a primary concern.
This study doesn’t FIX that structural incentive problem (if it exists, as I suspect it does). But it does something vital. It chips away at the “no proof” excuse that’s been sitting comfortably underneath it. And that’s worth a whole heck of a lot.
A Harder Sentence to Say With a Straight Face
None of this changes today’s reality for people like me, still fighting for coverage, still watching insurers point to a lack of long-term data as the reason to say no.
But data like this is exactly what eventually closes that argument down for good.
It probably won’t happen overnight. It rarely does. But every study like this one makes “there’s just no evidence” a harder sentence for an insurance company to say with a straight face.
Source:
Trends in Cost of Care With Tirzepatide in Adults Aged Over 55 Years With Obesity or Overweight Without Diabetes: A Matched Cohort Analysis, Diabetes Obesity and Metabolism, August 24, 2026, https://dom-pubs.onlinelibrary.wiley.com/doi/10.1111/dom.71250g
